Intensified competition in the industry, local pharmaceutical companies have begun to build production bases

[Pharmaceutical Network Market Analysis] At present, China's pharmaceutical industry has begun to accelerate into an accelerated period of transformation and upgradi.
In order to meet the growing demand for clinical services and improve production capacity and service efficiency, many pharmaceutical companies are currently expanding production and improving market competitiveness by building new production bas.
Recently, Hequan Pharmaceutical, a subsidiary of WuXi AppTec, announced that its new oligonucleotide and peptide production building located in the Changzhou API R&D and production base was officially put into operati.
After being put into production, Hequan Pharmaceutical will have 4 kilogram-scale large-scale oligonucleotide production lines, and more than 20 small-scale and medium-scale production lin.
The maximum total size of a single oligonucleotide synthesis will increase from 9 mol to 0 Moo.
The newly commissioned production building is an important part of Hequan's integrated novel molecular drug CRDMO (Contract Research, Development and Manufacturing Organization) platfo.
It is worth mentioning that before this, WuXi PharmaTech Tianjin R&D Base announced that Tianjin Rongda Park was officially put into operati.
WuXi AppTec Tianjin Rongda New Industrial Park, which has been put into operation, will provide great support for WuXi AppTec's Drug R&D International Service Department to expand R&D capacity and meet the growing R&D needs of custome.
In addition to WuXi AppTec, on June 7, the construction of the Longhua Science and Technology Industrial Park, the global supply chain headquarters base of Shenzhen Mindray Biomedical Electronics .
, L.
, officially start.
The Mindray Medical Longhua Base Project has a total investment of 2 billion yu.
It will build a medical device, in vitro diagnostic reagent manufacturing base and a series of supporting facilities to promote Mindray Medical to comprehensively upgrade its global supply chain layout and build the group's global supply chain headquarte.
According to the plan, by 2030, Mindray Longhua Base will carry more than 60% of the production capacity of the group's supply chain, and cooperate with Mindray Medical Shenzhen Guangming Base to form a two-wheel drive pattern, leading the total output value of Mindray Medical Shenzhen's manufacturing sector to exceed 1,000 in 203 billion targ.
On June 6, WuXi Biologics' new biologics plant .
5 (DP5) in Wuxi City, Jiangsu Province has also officially put into GMP producti.
This is the ninth biologics plant that WuXi Biologics has put into production global.

DP5 applies an advanced isolator filling production line, which can provide continuous and stable preparation filling services for 1mL slender, 1mL, 25mL, 3mL and other prefilled needles of different specificatio.

The filling speed of preparations can reach 400 pieces per minute, and the annual production capacity is as high as 17 million piec.

As many companies are expanding their production capacity, industry analysts believe that this is on the one hand to promote clinical pipelines, and on the other hand, it is also based on commercialization consideratio.

As a large number of innovative drugs continue to enter the clinical development stage and even go public, companies want to stand o.

, will increasingly require large-scale producti.

Therefore, judging from the current industry development trend, it is expected that pharmaceutical companies will choose to build and acquire production bases to expand the company's production capaci.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.